Grace Therapeutics develops reformulated medicines for rare diseases, led by an injectable form of nimodipine for patients with brain bleeding. It last closed at $1.71 on Nov 20, down 1.16% on the day. The next earnings report for GRCE is expected around Thu, Feb 11, 2027. For the quarter ended Sep 2026, GRCE reported EPS of -$0.11. Over its last 8 reports the stock moved an average of 2.6% the session after earnings. Over the last 12 months GRCE insiders bought $891K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is GRCE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GRCE.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on GRCEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
Technical AnalysisPrices may be delayed
GRCE · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 7% below its 20 day and 15% below its 50 day average. It is 57% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Nov 3) at $1.70, and the nearest resistance the Pivot at $1.74.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.6%/day
Key levels
$5.1852 week high+202.9%
$2.68200 day average+56.7%
$2.10100 day average+22.8%
$2.05Swing high (Oct 29)+19.9%
$1.9750 day average+15.2%
$1.8220 day average+6.4%
$1.79Pivot R1+4.7%
$1.74Pivot+1.8%
$1.71Last close
$1.70Swing low (Nov 3)−0.6%
$1.65Pivot S1−3.5%
$1.6452 week low−4.1%
Indicators
RSI (14)
34.71
Weak, oversold below 30
Neutral
MACD
-0.07
Below its signal line
Bearish
Stochastic
22.5
Middle of its range
Neutral
ADX (14)
31.4
Trending down
Williams %R
-81.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-120.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−7.6%
Change over 10 sessions
Bearish
ATR (14)
$0.11
Typical daily range, 6.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumFading
StretchNear oversold
VolatilityNormal, 18.0%/day
Key levels
$5.1852 week high+202.9%
$2.68200 day average+56.7%
$2.10100 day average+22.8%
$2.05Swing high (Oct 29)+19.9%
$1.9750 day average+15.2%
$1.8220 day average+6.4%
$1.79Pivot R1+4.7%
$1.74Pivot+1.8%
$1.71Last close
$1.70Swing low (Nov 3)−0.6%
$1.65Pivot S1−3.5%
$1.6452 week low−4.1%
Indicators
RSI (14)
33.24
Weak, oversold below 30
Neutral
MACD
-0.26
Above its signal line
Bullish
Stochastic
16.4
Near the bottom of its range
Oversold
ADX (14)
34.1
Trending down
Williams %R
-91.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-169.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.0%
Change over 10 sessions
Bearish
ATR (14)
$0.31
Typical daily range, 18.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for GRCE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how GRCE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for GRCEHow many large options trades hit GRCE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in GRCE in the last 90 days.
From SEC Form 4 filings by GRCE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRCE is in one of them and how their past GRCE trades turned out.
Grace Therapeutics is a pharmaceutical company based in Princeton, New Jersey, that develops reformulated versions of existing medicines for rare and orphan diseases. Its lead candidate, GTx-104, is an injectable form of nimodipine designed for intravenous delivery to patients with aneurysmal subarachnoid hemorrhage, a type of stroke. Its target customers include hospitals, physicians and patients. Its product candidates are still in development and have not yet been approved for sale.